Previous 10 | Next 10 |
Immunocore Holdings (IMCR) announces the dosing of the first patient in the first-in-human clinical trial of IMC-I109V, a new class of bispecific protein immunotherapy that is being developed for the treatment of patients with chronic hepatitis B ((HBV)) infection ((CHB)).The trial ...
PRESS RELEASE Immunocore announces dosing of first patient with ImmTAV ® bispecific molecule for chronic Hepatitis B IMC-I109V studied for the treatment of non- cirrhotic HBeAg -negative chronic hepatitis B (HBV) i...
Immunocore (IMCR): Q1 net loss of $40.05M.Revenue of $11.4M beats by $1.22M.Press Release For further details see: Immunocore beats on revenue
PRESS RELEASE Immunocore Reports First Quarter 202 1 Financial Results Biologics License Application (BLA) submission to the U.S. Food and Drug Administration ( FDA ) is expected to be complet ed in third ...
PRESS RELEASE Immunocore Announces Upcoming Presentations at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting Overall survival benefit from tebentafusp in patients with best response of progressive disea...
Immunocore (IMCR) announces positive data from a phase 3 randomized trial comparing tebentafusp (IMCgp100) with investigator’s choice in first-line metastatic uveal melanoma ((mUM)) in the clinical trial plenary session at the American Association for Cancer Research ((AACR))...
PRESS RELEASE Immunocore presents phase 3 data comparing tebentafusp with investigator’s choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual Meeting Tebentafusp is the first investigational therapy to im...
Immunocore is a "platform" pharmaceutical company looking to help naïve T cells recognize and kill their targets. Their technology involves soluble TCRs that recognize markers that indicate whether a cell is cancerous or infected with a virus. Their lead asset, tebentafusp, i...
Immunocore (IMCR): FY GAAP EPS of -$2.79 beats by $9.00.Revenue of $30.1M (+17.1% Y/Y) misses by $7.44M.Press Release For further details see: Immunocore EPS beats by $9.00, misses on revenue
Immunocore Provides Business Update and Reports Full Year 2020 Financial Results Breakthrough Therapy Designation granted by the FDA for tebentafusp in unresectable or metastatic uveal melanoma Tebentafusp Phase 3 randomized trial data subject of an o...
News, Short Squeeze, Breakout and More Instantly...
Immunocore Holdings plc Company Name:
IMCR Stock Symbol:
NASDAQ Market:
Immunocore Holdings plc Website:
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 73.0% to $0.4585 on volume of 640,087,036 shares Ocean Power Technologies Inc. (OPTT) rose 34.9% to $0.1812 on volume of 396,326,565 shares NVIDIA Corporation (NVDA) rose 0.2% to $1...
A look at the top 10 most actives in the United States NLS Pharmaceutics Ltd. (NLSP) rose 156.2% to $0.38 on volume of 125,047,059 shares Reliance Global Group Inc. (RELI) rose 210.8% to $0.69 on volume of 110,427,102 shares Mustang Bio Inc. (MBIO) rose 53.3% to $1.15 on volume of 87,727,...
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma The Phase 3 PRISM-MEL-301 trial will study the efficacy and safety of brenetafusp (IMC-F10...